Institutional investors purchased a net $10.0 million shares of IMMU during the quarter ended March 2017, and now own 63.05% of the total float, a percentage that is typical for companies in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 4.6 Million shares of Immunomedics Inc
FARALLON CAPITAL MANAGEMENT LLC Bought 4.2 Million shares of Immunomedics Inc
REDMILE GROUP LLC Bought 3.4 Million shares of Immunomedics Inc